This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Amgen Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: The Innovative Contributions of Salman Yojiro Jabri
Introduction
Salman Yojiro Jabri is a notable inventor based in Aptos, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific proteins associated with cancer.
Latest Patents
Jabri holds a patent for "Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists." This patent includes myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using these compounds. The compounds described in the patent may be utilized in the treatment of various diseases, including cancer.
Career Highlights
Currently, Jabri is associated with Amgen Inc., a leading biotechnology company. His work focuses on innovative solutions that address critical health challenges through advanced pharmaceutical research.
Collaborations
Throughout his career, Jabri has collaborated with talented individuals such as Gwenaella Rescourio and Ana Zurisadai Gonzalez Buenrostro. These collaborations have contributed to the advancement of his research and the development of effective pharmaceutical solutions.
Conclusion
Salman Yojiro Jabri's work exemplifies the impact of innovative thinking in the pharmaceutical industry. His contributions, particularly in cancer treatment, highlight the importance of research and collaboration in advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile